Cage Bio Inc.

CAGE Bio Inc. has started a Phase 2b trial for CGB-500, a topical JAK inhibitor for moderate to severe atopic dermatitis, aiming to optimize dosing and assess safety and efficacy. The ointment uses ionic liquid technology for targeted treatment, showing a 95% success rate in Phase 2a. The trial involves 180 participants, focusing on efficacy and side effects balance, with minimal systemic exposure for localized relief.

DelveInsight's 'Rosacea Pipeline Insight, 2024' report highlights 25+ key companies developing 25+ pipeline drugs for Rosacea, with therapies in various stages of clinical development. Key companies include Sol-Gel Technologies, Maruho Co., Ltd., AOBiome LLC, and others. Emerging therapies like Epsolay, M 1220, and BMX-010 are expected to impact the market. Regulatory approvals and collaborations are noted, such as Sol-Gel Technologies' agreement with Searchlight Pharma Inc. and Zydus Lifesciences' FDA approval for Metronidazole Topical cream.

Nitin Joshi, CEO of CAGE Bio Inc., discussed the company's progress in dermatological drug development, focusing on CGB-500, an ionic liquid formulation of 1% tofacitinib for atopic dermatitis. Phase 2 trials showed significant efficacy, with 95% of patients achieving clear or almost clear skin. Joshi highlighted the formulation's efficiency in delivering drugs through the skin barrier, aiming for biologic-level efficacy with topical safety. Plans include extending CGB-500's use to alopecia areata and vitiligo, emphasizing localized treatment's importance in dermatology.